The emerging spectrum of allelic variation in schizophrenia: current evidence and strategies for the identification and functional characterization of common and rare variants

被引:65
|
作者
Mowry, B. J. [1 ,2 ]
Gratten, J. [1 ]
机构
[1] Univ Queensland, Queensland Brain Inst, Brisbane, Qld 4072, Australia
[2] Queensland Ctr Mental Hlth Res, Brisbane, Qld, Australia
基金
英国医学研究理事会;
关键词
CNV; functional genomics; GWAS; schizophrenia; sequencing; SNP; GENOME-WIDE ASSOCIATION; COPY NUMBER VARIANTS; 3Q29 MICRODELETION SYNDROME; INDIVIDUAL GENETIC RISK; PLURIPOTENT STEM-CELLS; BIPOLAR DISORDER; SUSCEPTIBILITY LOCI; PSYCHOTIC ILLNESS; NICOTINIC AGONIST; BRAIN-DEVELOPMENT;
D O I
10.1038/mp.2012.34
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
After decades of halting progress, recent large genome-wide association studies (GWAS) are finally shining light on the genetic architecture of schizophrenia. The picture emerging is one of sobering complexity, involving large numbers of risk alleles across the entire allelic spectrum. The aims of this article are to summarize the key genetic findings to date and to compare and contrast methods for identifying additional risk alleles, including GWAS, targeted genotyping and sequencing. A further aim is to consider the challenges and opportunities involved in determining the functional basis of genetic associations, for instance using functional genomics, cellular models, animal models and imaging genetics. We conclude that diverse approaches will be required to identify and functionally characterize the full spectrum of risk variants for schizophrenia. These efforts should adhere to the stringent standards of statistical association developed for GWAS and are likely to entail very large sample sizes. Nonetheless, now more than any previous time, there are reasons for optimism and the ultimate goal of personalized interventions and therapeutics, although still distant, no longer seems unattainable. Molecular Psychiatry (2013) 18, 38-52; doi:10.1038/mp.2012.34; published online 1 May 2012
引用
收藏
页码:38 / 52
页数:15
相关论文
共 35 条
  • [31] Identification and functional characterization of two rare LDLR stop gain variants (p.c231*and p.R744*) in Saudi familial hypercholesterolemia patients
    Awan, Zuhier
    Batran, Alhanuf
    Al-allaf, Faisal A.
    Alharbi, Raneem S.
    Hegazy, Gehan A.
    Jamalalail, Bassam
    Almansouri, Majid
    Bima, Abdulhadi I.
    Almukadi, Haifa
    Kutbi, Hussam I.
    Altayar, Ahmed E.
    Banaganapalli, Babajan
    Shaik, Noor A.
    PANMINERVA MEDICA, 2023, 65 (04) : 479 - 490
  • [32] Identification and functional characterization of two novel SRD5A2 variants in Iranian siblings with 5α-reductase type 2 deficiency: Expanding the mutational spectrum and implications for genetic diagnosis
    Ordooei, Mahtab
    Zamani, Nasrin
    Rabbani, Bahareh
    Mahdieh, Nejat
    HUMAN GENE, 2025, 43
  • [33] Complex Analysis of Urate Transporters SLC2A9, SLC22A12 and Functional Characterization of Non-Synonymous Allelic Variants of GLUT9 in the Czech Population: No Evidence of Effect on Hyperuricemia and Gout
    Hurba, Olha
    Mancikova, Andrea
    Krylov, Vladimir
    Pavlikova, Marketa
    Pavelka, Karel
    Stiburkova, Blanka
    PLOS ONE, 2014, 9 (09):
  • [34] Functional characterization of a common CYP4F11 genetic variant and identification of functionally defective CYP4F11 variants in erythromycin metabolism and 20-HETE synthesis
    Yi, Myeongjin
    Cho, Sun-Ah
    Min, Jungki
    Kim, Dong Hyun
    Shin, Jae-Gook
    Lee, Su-Jun
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2017, 620 : 43 - 51
  • [35] IDENTIFICATION OF RARE DISRUPTIVE VARIANTS IN VOLTAGE-GATED CHANNEL GENES (CACNA1C, CACNA1D, CACNA1S, CACNA1I) IN JAPANESE SAMPLES OF SCHIZOPHRENIA AND AUTISM SPECTRUM DISORDER USING ION TORRENT PGM PLATFORM
    Wang, Chenyao
    Kimura, Hiroki
    Xing, Jingrui
    Ishizuka, Kanoko
    Kushima, Itaru
    Arioka, Yuko
    Yoshimi, Akira
    Nakamura, Yukako
    Shiino, Yomoko
    Oya, Yuko
    Takasaki, Yuto
    Aleksic, Branko
    Mori, Daisuke
    Ozaki, Norio
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S341 - S342